Oral Rivaroxaban in Children With Venous Thrombosis
Public ClinicalTrials.gov record NCT01684423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
30-day, Single-arm Study of the Safety, Efficacy and the Pharmacokinetic and Pharmacodynamic Properties of Oral Rivaroxaban in Children With Various Manifestations of Venous Thrombosis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out whether rivaroxaban is safe to use in children and how long it stays in the body. There will also be a check for bleeding and worsening of blood clots.
Study identification
- NCT ID
- NCT01684423
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 64 participants
Conditions and interventions
Conditions
Interventions
- Rivaroxaban (Xarelto, BAY59-7939) Drug
- Active comparator Drug
- Rivaroxaban (BAY59-7939) suspension Drug
Drug
Eligibility (public fields only)
- Age range
- 6 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 19, 2013 (Actual)
- Primary completion
- Sep 1, 2016 (Actual)
- Completion
- Sep 1, 2016 (Actual)
- Last update posted
- Sep 21, 2017
2013 – 2016
United States locations
- U.S. sites
- 13
- U.S. states
- 11
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Little Rock | Arkansas | 72202-3500 | — |
| Not listed | Los Angeles | California | 90027-6089 | — |
| Not listed | Orange | California | 92868-3974 | — |
| Not listed | Chicago | Illinois | 60611 | — |
| Not listed | Indianapolis | Indiana | 46202 | — |
| Not listed | Detroit | Michigan | 48201-2196 | — |
| Not listed | Minneapolis | Minnesota | 55404 | — |
| Not listed | New Hyde Park | New York | 11040 | — |
| Not listed | Cleveland | Ohio | 44106-2602 | — |
| Not listed | Columbus | Ohio | 43205-2696 | — |
| Not listed | Philadelphia | Pennsylvania | 19104 | — |
| Not listed | Houston | Texas | 77030 | — |
| Not listed | Richmond | Virginia | 23298 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 46 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01684423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 21, 2017 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01684423 live on ClinicalTrials.gov.